Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Ondas Inc.: Ondas Secures U.S. Army Order for Lethal Unmanned Systems for Over $50 Million (Accesswire) +++ ONDAS Aktie +3,27%

SERES THERAPEUTICS Aktie

 >Aktienkurs 
4.88 EUR    (TradegateBSX)
Ask: 4.99 EUR / 600 Stück
Bid: 4.77 EUR / 630 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>Performance
1 Woche: +8,7%
1 Monat: -32,3%
3 Monate: -35,4%
6 Monate: -60,7%
1 Jahr: -63,3%
laufendes Jahr: -63,9%
>SERES THERAPEUTICS Aktie
Name:  SERES THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US81750R2013 / A413XF
Symbol/ Ticker:  1S90 (Frankfurt) / MCRB (NASDAQ)
Kürzel:  FRA:1S90, ETR:1S90, 1S90:GR, NASDAQ:MCRB
Index:  -
Profil:  Seres Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing live biotherapeutics for serious diseases linked to the human microbiome. Its current work centers on treatments designed to prevent bacterial bloodstream infect..
>Volltext..
Marktkapitalisierung:  44.09 Mio. EUR
Unternehmenswert:  88.03 Mio. EUR
Umsatz:  0.99 Mio. EUR
EBITDA:  -71.88 Mio. EUR
Nettogewinn:  -40.67 Mio. EUR
Gewinn je Aktie:  -4.35 EUR
Schulden:  69.81 Mio. EUR
Liquide Mittel:  25.87 Mio. EUR
Operativer Cashflow:  -36.56 Mio. EUR
Bargeldquote:  1.54
Umsatzwachstum:  -
Gewinnwachstum:  36.41%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel -
Suchwörter:  SERES THERAPEUTICS, SERES THERAPEUTIC
Letzte Datenerhebung:  05.08.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 9.68 Mio. St.
Frei handelbar: 75.79%
Rückkaufquote: -25.86%
Mitarbeiter: 66
Umsatz/Mitarb.: 0.01 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 223.81%
Bewertung:
KGV: -
KGV lG: -
KUV: 42.02
KBV: 1.9
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -234.61%
Gewinnmarge: -4088.84%
Operative Marge: -7561.29%
Managementeffizenz:
Gesamtkaprendite: -33.29%
Eigenkaprendite: -121.87%
>Peer Group
Gesundheit, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika, Magen-Darm-Erkrankungen & -behandlung
 
05.08.26 - 13:36
Seres Therapeutics EPS of $0.47, revenue of $0.74M beats by $0.56M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.07.26 - 13:03
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment (GlobeNewswire EN)
 
80% of SER-155 recipients achieved immunosuppressive-free clinical response of diarrhea (a primary symptom of irEC) at Day 15 in the Investigator-Sponsored Trial (IST) conducted by Memorial Sloan Kettering Cancer Center (MSK)...
25.06.26 - 13:03
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres′ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (GlobeNewswire EN)
 
CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line results from an investigator-sponsored trial (IST) evaluating SER-155 in patients with immune checkpoint inhibitor-related enterocolitis, a serious and frequent side effect of immune checkpoint inhibitor cancer therapy. The IST was conducted at Memorial Sloan Kettering Cancer Center, with which Seres has a long history of collaboration, by Principal Investigator David Faleck, M.D., Director of Inflammatory and Immune-Related Bowel Diseases. The webcast will occur on July 8, 2026, at 8:30 am ET....
05.06.26 - 13:03
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027 (GlobeNewswire EN)
 
Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones...
20.05.26 - 00:01
Insiderhandel: Vorstand verkauft Aktien von Seres Therapeutics im Wert von 444 USD (Insiderkauf)
 
Brady, Kelly - Vorstand - Tag der Transaktion: 2026-05-18...
20.05.26 - 00:01
Insiderhandel: Vorstand verkauft Aktien von Seres Therapeutics im Wert von 595 USD (Insiderkauf)
 
Desrosier, Thomas - Vorstand - Tag der Transaktion: 2026-05-18...
20.05.26 - 00:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Seres Therapeutics im Wert von 1950 USD (Insiderkauf)
 
Shaff, Eric D. - Aufsichtsrat - Tag der Transaktion: 2026-05-18...
20.05.26 - 00:01
Insiderhandel: Vorstand verkauft Aktien von Seres Therapeutics im Wert von 580 USD (Insiderkauf)
 
Henn, Matthew R. - Vorstand - Tag der Transaktion: 2026-05-18...
12.05.26 - 13:03
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference (GlobeNewswire EN)
 
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference and will present a company overview at 3:30 p.m. ET on May 19, 2026....
04.05.26 - 13:03
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease (GlobeNewswire EN)
 
Data highlight both SER-603's rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomarkers that inform response to biologics and patient stratification...
20.04.26 - 13:03
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 (GlobeNewswire EN)
 
Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration...
09.04.26 - 13:03
Seres Therapeutics to Present at CARB-X Investor Day (GlobeNewswire EN)
 
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X Investor Day on April 16, 2026, which precedes the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Munich, Germany. CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global nonprofit partnership accelerating the development of new antibacterial products to address drug-resistant bacteria. The CARB-X Investor Day brings together pharmaceutical and biotech product developers, investors, and partners working to combat antimicrobial resistance (AMR). The World Health Organization declared AMR as a top ten global public health threat, with estimates that yearly deaths may reach 10 million by 2050, putting mortality due to AMR on par with deaths due to cancer. The event will feature presentations on innovative therapeu...
12.03.26 - 20:42
Seres Therapeutics GAAP EPS of $0.64, revenue of $0.78M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.03.26 - 12:03
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire EN)
 
Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track for Q2 2026 ...
02.03.26 - 22:30
Seres Therapeutics appoints Richard Kender as interim CEO (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
02.03.26 - 22:09
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates (GlobeNewswire EN)
 
Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience...
19.02.26 - 02:01
Insiderhandel: Vorstand verkauft Aktien von Seres Therapeutics im Wert von 754 USD (Insiderkauf)
 
Henn, Matthew R. - Vorstand - Tag der Transaktion: 2026-02-15...
19.02.26 - 02:01
Insiderhandel: Aufsichtsrat verkauft Aktien von Seres Therapeutics im Wert von 2194 USD (Insiderkauf)
 
Shaff, Eric D. - Aufsichtsrat - Tag der Transaktion: 2026-02-15...
19.02.26 - 02:01
Insiderhandel: Vorstand verkauft Aktien von Seres Therapeutics im Wert von 635 USD (Insiderkauf)
 
Young, Teresa L. - Vorstand - Tag der Transaktion: 2026-02-15...
19.02.26 - 02:01
Insiderhandel: Vorstand verkauft Aktien von Seres Therapeutics im Wert von 661 USD (Insiderkauf)
 
Desrosier, Thomas - Vorstand - Tag der Transaktion: 2026-02-15...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Um einen Graben zu füllen, muß ein Hügel abgetragen werden. - Sprichwort Armenien
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!